Screener
Krystal Biotech, Inc. KRYS Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except par value) | March 31,2026 | December 31,2025 |
|---|---|---|
| Current portion of lease liability | 1,800 | 1,771 |
| Accrued rebates | 70,717 | 58,181 |
| Accrued expenses and other current liabilities | 31,196 | 39,752 |
| Total current liabilities | 107,802 | 102,942 |
| Lease liability | 7,312 | 7,568 |
| Other long-term liabilities | 5,124 | 3,724 |
| Total liabilities | 120,238 | 114,234 |
| Commitments and contingencies (see note 7) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s total current liabilities?
- Krystal Biotech, Inc. (KRYS) reported total current liabilities of $107.8M in Q1 2026.
- How has Krystal Biotech, Inc.'s total current liabilities changed year-over-year?
- Krystal Biotech, Inc.'s total current liabilities increased by 35.6% year-over-year, from $79.49M to $107.8M.
- What is the long-term trend for Krystal Biotech, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s total current liabilities has grown at a 46.1% compound annual growth rate (CAGR), from $15.45M to $102.94M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Krystal Biotech, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude